Infosys Limited
$48.32B- Market cap
- $45.22B
- Debt
- +$5.96B
- Cash
- −$2.86B
Capital structure 88% equity / 12% debt · EV / Revenue 2.51x · EV / EBITDA 15.28x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $45.22B · View financials
Snapshot Sep 8, 9:59 AM ET
FY 2025 ·
Decision snapshot: INFY stock price at discount vs BMRN $11.15 current versus $27.92 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMRN's multiple
Implied fair value · at INFY's multiple
Snapshot Sep 8, 10:03 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INFY FY 2025 (ended Mar 31, 2025) · BMRN FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 88% equity / 12% debt · EV / Revenue 2.51x · EV / EBITDA 15.28x
Capital structure 96% equity / 4% debt · EV / Revenue 3.72x · EV / EBITDA 21.23x
INFY carries the larger enterprise value at $48.32B against $11.99B; INFY trades on the lower EV / Revenue multiple (2.51x vs 3.72x); INFY on the lower EV / EBITDA (15.28x vs 21.23x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
INFOSYS LIMITED · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
0.08x
Net debt / EBITDA
Leverage against operating earnings
0.98x
-1.43x
Cash and equivalents
Liquid reserves on the balance sheet
$2.86B
$1.31B
Total debt
Interest-bearing obligations outstanding
$5.96B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Accenture plc
INFY vs ACN
COGNIZANT TECHNOLOGY SOLUTIONS CORP
INFY vs CTSH
INTERNATIONAL BUSINESS MACHINES CORP
INFY vs IBM
DXC Technology Co
INFY vs DXC
VERTEX PHARMACEUTICALS INC / MA
INFY vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
INFY vs ALNY
Sarepta Therapeutics, Inc.
INFY vs SRPT
REGENXBIO Inc.
INFY vs RGNX
IONIS PHARMACEUTICALS INC
INFY vs IONS
PTC THERAPEUTICS, INC.
INFY vs PTCT
$505.32M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.